Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
natural tags : Cancer save search
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
Published: 2024-02-07 (Crawled : 00:00) - biospace.com/
MAIA | $2.15 9.69% 0.0% 100K
|
|
| O: 0.0%
H: 0.0%
C: -3.4%
lung positive cancer publication cell treatment communications potential
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
ACHL | $0.7827 -2.16% -2.21% 200K
|
Manufacturing
|
| O: 0.98%
H: 1.09%
C: -0.52%
cancer publication therapeutics
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2023-11-04 (Crawled : 12:20) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
gda-201 candidate natural cancer cell immunotherapy meeting therapy
Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy
Published: 2023-10-04 (Crawled : 15:00) - prnewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
cls-484 cancer preclinical immunotherapy potential results
Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer
Published: 2023-08-08 (Crawled : 03:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 2.58%
H: 0.41%
C: -1.13%
ibi363 antibody cancer preclinical results
Natural Killer Cells Therapeutics Market Analysis and Industry Forecast Report 2023: Focus on Cancer Immunotherapy, Infectious Diseases and Autoimmune Disorders
Published: 2023-07-27 (Crawled : 18:00) - prnewswire.com
AFMD | $5.15 1.58% 1.55% 64K
|
Health Technology
|
| O: 0.18%
H: 6.85%
C: 4.03%
report natural cancer therapeutics market
Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients
Published: 2023-07-10 (Crawled : 14:00) - nantkwest.com
IBRX | $5.265 7.23% 6.74% 4.6M
|
Manufacturing
|
| O: 0.0%
H: 2.76%
C: -2.21%
natural cancer tumor plus study
Natural State Laboratories Chooses SOPHiA GENETICS to Help Launch their In-House Hereditary Cancer Testing
Published: 2023-05-16 (Crawled : 13:00) - prnewswire.com
SOPH | $4.93 2.71% 2.64% 51K
|
|
| O: 0.45%
H: 1.12%
C: -5.58%
state natural cancer
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-05-08 (Crawled : 12:00) - globenewswire.com
INMB | $8.33 -5.34% -5.64% 69K
|
Health Technology
|
| O: 4.71%
H: 6.64%
C: -0.89%
fda natural cancer clearance application trial
New Study Findings Published in Nature Show Circulating Tumor DNA (ctDNA) Can Predict and Detect Cancer Recurrence Earlier In Non-Small Cell Lung Cancer
Published: 2023-04-13 (Crawled : 14:00) - biospace.com/
NVTA | $0.019 0.0% 22M
|
Health Services
|
| O: 3.05%
H: 9.63%
C: 5.93%
lung cancer cell tumor dna show study
Natera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal Cancer
Published: 2023-01-17 (Crawled : 14:20) - biospace.com/
NTRA S | $85.275 -2.3% -2.35% 2.5M
|
Health Services
|
| O: -1.05%
H: 1.4%
C: -3.33%
cancer publication study
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™
Published: 2022-12-08 (Crawled : 13:20) - globenewswire.com
INMB | $8.33 -5.34% -5.64% 69K
|
Health Technology
|
| O: 0.0%
H: 10.31%
C: 6.56%
day treatment cancer platform aml
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
Published: 2022-10-07 (Crawled : 13:20) - globenewswire.com
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: 2.41%
H: 4.38%
C: -10.09%
treatment communications cancer publication platform
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
Published: 2022-10-06 (Crawled : 13:00) - biospace.com/
ACHL | $0.7827 -2.16% -2.21% 200K
|
Manufacturing
|
| O: -2.59%
H: 5.51%
C: 0.44%
therapeutics therapy cancer
CytoImmune Therapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Trial Evaluating a Novel Off-the-Shelf Engineered Natural Killer Cellular Therapy for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-07-28 (Crawled : 13:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
treatment trial therapeutics therapy cancer
Isleworth Healthcare Acquisition Corp. and Cytovia Therapeutics Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Empowering Natural Killer Cell Therapeutics to Fight Cancer
Published: 2022-04-26 (Crawled : 22:00) - prnewswire.com
ISLE | $10.01 0.1%
|
|
| O: 0.0%
H: 0.1%
C: 0.0%
acquisition therapeutics cancer
Merus Announces Publication in Nature Cancer on Petosemtamab’s (MCLA-158) Unique Mechanism of Action
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
MRUS | $39.83 -1.58% -1.61% 800K
|
Health Technology
|
| O: -0.13%
H: 3.04%
C: 2.06%
mcla-158 unique cancer publication
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity
Published: 2022-03-17 (Crawled : 19:00) - biospace.com/
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 3.95%
H: 5.7%
C: 2.53%
biotech cel preclinical cancer iot pre-clinical
Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer
Published: 2021-11-29 (Crawled : 14:30) - biospace.com/
CELU | News F | $3.09 -3.74% -3.88% 24K
|
|
| O: 1.48%
H: 2.19%
C: -2.19%
new drug fda clearance application drug fda clearance positive therapy cancer her2- her2
Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting
Published: 2021-11-15 (Crawled : 13:30) - globenewswire.com
CELU | News F | $3.09 -3.74% -3.88% 24K
|
|
| O: -1.8%
H: 0.0%
C: -4.22%
preclinical genetic immunotherapy therapy cancer pre-clinical
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.